(Approval lapsed) SINEMET CR (carbidopa/levodopa) 50 mg/200 mg Prolonged-Release Tablets
Section 19A approved medicine
(Approval lapsed) SINEMET CR (carbidopa/levodopa) 50 mg/200 mg Prolonged-Release Tablets
Section 19A approval holder
Merck Sharp & Dohme (Australia) Pty Limited ABN 14 000 173 508
Phone
1800 818 553
Approved until
Status
Expired
Medicines in short supply/unavailable
SINEMET CR levodopa/carbidopa 200 mg/50 mg modified release tablet bottle - ARTG 171694
Indication(s)
Idiopathic parkinsonism, where standard formulations containing levodopa/carbidopa have produced inadequate control. Experience is limited in patients who have not been treated with levodopa before.